Jose R. Conejo-Garcia

Tumor Microenvironment and Metastasis Program, Wistar Institute

Research Area

Biography

Jose R. Conejo-Garcia has not added Biography.
If you are Jose R. Conejo-Garcia and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 27	2014

Other Publications

Article	Year
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 20400704	2010
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England journal of medicine\| PubMed ID: 12529460	2003
Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer biology & therapy\| PubMed ID: 14508119	2003
Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer research\| PubMed ID: 15026360	2004
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature medicine\| PubMed ID: 15322536	2004
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nature medicine\| PubMed ID: 15334073	2004
Vascular leukocytes contribute to tumor vascularization. Blood\| PubMed ID: 15358628	2005
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 15925544	2005
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Human gene therapy\| PubMed ID: 15960607	2005
Immunotherapy for gynaecological malignancies. Expert opinion on biological therapy\| PubMed ID: 16120050	2005
Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer biology & therapy\| PubMed ID: 16627987	2006
Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer biology & therapy\| PubMed ID: 16861891	2006
Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Advances in experimental medicine and biology\| PubMed ID: 17191386	2007
Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer research\| PubMed ID: 17510407	2007
Role of vascular leukocytes in ovarian cancer neovascularization. Advances in experimental medicine and biology\| PubMed ID: 18546635	2008
PILAR is a novel modulator of human T-cell expansion. Blood\| PubMed ID: 18550855	2008
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer research\| PubMed ID: 18768667	2008
Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. Journal of translational medicine\| PubMed ID: 19545375	2009
CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer research\| PubMed ID: 19602595	2009
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. The Journal of clinical investigation\| PubMed ID: 19620771	2009
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer research\| PubMed ID: 19738057	2009
Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future oncology (London, England)\| PubMed ID: 19852731	2009
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell cycle (Georgetown, Tex.)\| PubMed ID: 20023378	2010
Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration. The Journal of experimental medicine\| PubMed ID: 20212068	2010
Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20682703	2010
Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. Clinical & developmental immunology\| PubMed ID: 21076522	2010
CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget\| PubMed ID: 21113407	2010
It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses. Cell cycle (Georgetown, Tex.)\| PubMed ID: 21270530	2011
Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer research\| PubMed ID: 22307839	2012
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. The Journal of experimental medicine\| PubMed ID: 22351930	2012
Double agents in the war on cancer: leukocytes govern ovarian cancer progression. Oncotarget\| PubMed ID: 22538964	2012
Mast cells impair the development of protective anti-tumor immunity. Cancer immunology, immunotherapy : CII\| PubMed ID: 22684520	2012
Does the F508-CFTR mutation induce a proinflammatory response in human airway epithelial cells? American journal of physiology. Lung cellular and molecular physiology\| PubMed ID: 22821996	2012
Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Integrative biology : quantitative biosciences from nano to macro\| PubMed ID: 22935885	2013
Editorial: A clear vision needs some balance. Journal of leukocyte biology\| PubMed ID: 23118443	2012
Anti-tumor immunity: myeloid leukocytes control the immune landscape. Cellular immunology\| PubMed ID: 23121972	2012
Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles. Oncoimmunology\| PubMed ID: 23162774	2012
Avirulent Toxoplasma gondii Generates Therapeutic Antitumor Immunity by Reversing Immunosuppression in the Ovarian Cancer Microenvironment. Cancer research\| PubMed ID: 23704211	2013
Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell cycle (Georgetown, Tex.)\| PubMed ID: 23759589	2013
A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis. Journal of cellular physiology\| PubMed ID: 23765988	2014
Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. Expert review of obstetrics & gynecology\| PubMed ID: 24039628	2012
Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer. Frontiers in immunology\| PubMed ID: 24339824	2013
Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. Nanomedicine : nanotechnology, biology, and medicine\| PubMed ID: 24566274	2014